CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful conscientiously but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past few shares. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire interview which I came away with a bad opinion of the company.

Irony of irony, the bad opinion of mine of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how and linked intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) along with the first new drug application endorsement ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this individual treatment in addition to a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active company with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Could it all be smoke and mirrors? That’s a question I have been asking myself with the really start of the interest of mine in this business. Judging by way of the multiples of a huge number of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News